A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

2019 ◽  
Author(s):  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Intravesical Chemotherapy ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer

2018 ◽  
Vol 102 (1) ◽  
pp. 60-68 ◽  
Author(s):  
Wojciech Krajewski ◽  
Romuald Zdrojowy ◽  
Janusz Dembowski ◽  
Sławomir Poletajew ◽  
Michał Wróbel ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Invasive Bladder Cancer ◽  
Optimal Timing ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure

2021 ◽  
Vol 15 (1) ◽  
pp. 33-38
Author(s):  
Govind Shantharam ◽  
Ali Amin ◽  
Jorge Pereira ◽  
Ohad Kott ◽  
Catrina Mueller-Leonhard ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document